FDA has hard a decision to make, on one hand, the data is
showing convincing efficacy, the science is solid
behind the data and the medical KOLs should ask and support
stopping the trial for approval, on the other hand, FDA
has to be flexible. I am betting on FDA making the right
decision and stop the trial to file for approval.